Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Panelists discuss how healthcare resource utilization is primarily driven by hospitalizations, medication costs, and ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Body weight significantly influenced right heart function and survival in pulmonary arterial hypertension, with both extremes ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received positive topline results ...

Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.

New columnist Jolie Lizana shares her harrowing journey to a pulmonary hypertension diagnosis and finding purpose in advocacy ...

The pulmonary arterial hypertension market is expected to reach USD 2,080.7 million by 2025 and is expected to steadily grow at a CAGR of 2.3% to reach USD 2,612.0 million by 2035.